Morepen Laboratories Ltd Stock Price Today (NSE: MOREPENLAB)
Fundamental Score
Morepen Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Morepen Laboratories Ltd share price today is ₹51.48, down 1.53% on NSE/BSE as of 17 June 2026. Morepen Laboratories Ltd (MOREPENLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.38K (Cr). The 52-week high for MOREPENLAB share price is ₹66.40 and the 52-week low is ₹33.05. At a P/E ratio of 31.50x, MOREPENLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.78% and a debt-to-equity ratio of 0.13.
Morepen Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Morepen Laboratories Ltd share price chart: -2.43% return over the past month. 52-week high ₹66.40, 52-week low ₹33.05.
Morepen Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹46.56 | ₹46.57 | ₹44.94 | ₹45.79 | 45.06L (Cr) | |
| ₹43.77 | ₹49.49 | ₹43.51 | ₹46.51 | 315.93L (Cr) | |
| ₹42.20 | ₹45.50 | ₹42.20 | ₹43.24 | 85.86L (Cr) | |
| ₹42.22 | ₹42.22 | ₹42.22 | ₹42.22 | 0.00 (Cr) | |
| ₹42.80 | ₹42.80 | ₹41.38 | ₹42.22 | 74.63L (Cr) | |
| ₹44.00 | ₹45.45 | ₹43.61 | ₹43.92 | 45.54L (Cr) | |
| ₹43.45 | ₹44.04 | ₹43.00 | ₹43.72 | 22.82L (Cr) | |
| ₹43.19 | ₹44.79 | ₹42.51 | ₹42.91 | 39.92L (Cr) | |
| ₹43.44 | ₹43.76 | ₹42.82 | ₹42.98 | 22.36L (Cr) | |
| ₹41.49 | ₹42.90 | ₹41.10 | ₹42.52 | 26.75L (Cr) |
Morepen Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹43.77 | ₹49.49 | ₹43.51 | ₹45.79 | +4.62% | |
| ₹41.80 | ₹47.00 | ₹39.69 | ₹43.24 | +3.44% | |
| ₹34.56 | ₹44.18 | ₹34.56 | ₹41.36 | +19.68% | |
| ₹41.10 | ₹43.25 | ₹33.05 | ₹33.68 | -18.05% | |
| ₹36.63 | ₹48.84 | ₹34.83 | ₹43.67 | +19.22% | |
| ₹41.07 | ₹42.44 | ₹33.50 | ₹36.31 | -11.59% | |
| ₹43.60 | ₹44.40 | ₹38.42 | ₹41.07 | -5.80% | |
| ₹47.60 | ₹48.48 | ₹42.49 | ₹43.40 | -8.82% | |
| ₹48.13 | ₹50.38 | ₹47.51 | ₹47.58 | -1.14% | |
| ₹46.63 | ₹55.50 | ₹46.63 | ₹47.85 | +2.62% | |
| ₹58.50 | ₹59.34 | ₹45.28 | ₹46.63 | -20.29% | |
| ₹62.03 | ₹66.40 | ₹57.00 | ₹58.45 | -5.77% |
AI Research Briefing
Powered by Gemini · 2026-04-15
Morepen's CDMO story hinges on flawless execution of its large contract and securing new deals, a risky proposition given its small-cap status and negative free cash flow.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The India Pharma 2026 conference concluded on April 15, 2026, with discussions on strengthening the pharma ecosystem.
CORE STORY (THE REAL GAME)
- ₹825 crore CDMO contract win
- Q3FY26 profit increase of 3%
- Positive sentiment from India Pharma 2026
- New CDMO contract wins
- Faster-than-expected execution of existing contract
- API price stabilization
- Small-cap liquidity risk
- Negative free cash flow
- Execution risk on CDMO contract
FII decreased holdings by 0.1%. DII decreased holdings by 0.01%. Promoter holding steady.
India Pharma 2026 highlights the push for enhanced funding and infrastructure for the pharma sector.
₹825 crore multi-year CDMO contract from a global pharmaceutical company.
No. Free Cash Flow 5Y: ₹-444.19 Cr
Next 3-6 months depend on CDMO execution. Watch for revenue recognition and margin impact. Key is new contract wins to sustain growth.
Primary Thesis Risk
Failure to execute the CDMO contract will lead to a significant derating.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Morepen Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Morepen Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MOREPENLAB across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (15.08%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Consistent Growth Track Record (16.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (23.60% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (28.58% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.13)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-49.02%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-5.97%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-444.19 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Morepen Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Morepen Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Morepen Laboratories LtdMorepen Laborat...Selected✓ MOREPENLAB • 500288 | 34.5/100 | ₹51.48₹51 | ₹2379.21₹2379.21 | 31.50Average 31.5 Average | 11.78%Average 11.78% Average | 15.08%Good 15.08% Good | 0.13Excellent 0.1 Excellent | 28.58%Excellent 28.58% Excellent | 16.26%Excellent 16.26% Excellent | 0.46% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Morepen Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for MOREPENLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹2.20 | ₹41.07 | 18.7x |
| FY 2024 | ₹1.88 | ₹78.16 | 41.6x |
| FY 2023 | ₹0.77 | ₹48.55 | 63.1x |
| FY 2022 | ₹1.96 | ₹37.85 | 19.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Morepen Laboratories Ltd Quarterly Performance
Latest quarterly metrics for MOREPENLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-5.97%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-49.02%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.26%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
28.58%
Compounded annual net profit growth over 5 years
Morepen Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MOREPENLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Morepen Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Morepen Laboratories Ltd (MOREPENLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Morepen Laboratories Ltd
About MOREPENLAB (Morepen Laboratories Ltd)
Morepen Laboratories Ltd is a versatile pharmaceutical organization deeply rooted in the global healthcare landscape. With a firm commitment to innovation and quality, the company ...navigates a diverse portfolio encompassing the development, production, and distribution of a wide array of pharmaceutical products. From foundational Active Pharmaceutical Ingredients (APIs) that serve as building blocks for life-saving medications, to meticulously crafted branded and generic formulations, Morepen caters to varied therapeutic needs. Furthermore, their venture into home health products empowers individuals to proactively manage their well-being, reflecting a holistic approach to healthcare. This integrated structure allows Morepen to maintain a robust presence across multiple market segments, consistently striving to meet the evolving demands of patients and healthcare professionals worldwide. The company's API segment fuels the creation of essential drugs across a spectrum of therapeutic areas. Morepen produces the foundational components needed for medications addressing conditions such as allergies, respiratory ailments, high cholesterol, hypertension, diabetes, blood clotting disorders, digestive issues, and mental health disorders. Beyond APIs, Morepen formulates and markets a range of branded and generic medications, ensuring accessibility to vital treatments. This dual approach allows the company to cater to both large pharmaceutical manufacturers and individual consumers, expanding its reach and impact on global health. By consistently upholding stringent quality standards and investing in research and development, Morepen solidifies its position as a reliable supplier of essential pharmaceutical products. Morepen Laboratories extends its reach beyond prescription drugs by offering a suite of consumer-focused home health products. Recognizing the growing importance of self-monitoring and preventative care, they provide devices that allow individuals to actively manage their health from the comfort of their homes. This includes products designed to improve air quality, along with instruments for monitoring vital signs such as blood pressure and blood glucose levels. These products empower individuals to take a proactive role in their healthcare journey, fostering a sense of control and contributing to better overall health outcomes. By diversifying into the home health sector, Morepen demonstrates its commitment to providing comprehensive healthcare solutions that address a wide range of needs.
Company Details
Key Leadership
Corporate Events
MOREPENLAB Share Price: Frequently Asked Questions
What is the current share price of Morepen Laboratories Ltd?
Morepen Laboratories Ltd (MOREPENLAB) trades at ₹51.48 on NSE and BSE. Market cap ₹2.38K (Cr). Educational data only.
What is the P/E ratio of Morepen Laboratories Ltd?
Morepen Laboratories Ltd has a P/E of 31.50x vs industry average 31.77x.
What is the Bull Run score for Morepen Laboratories Ltd?
Morepen Laboratories Ltd has a Bull Run score of 34.5/100 based on 25+ financial parameters.
Does Morepen Laboratories Ltd pay dividends?
Morepen Laboratories Ltd has a dividend yield of 0.46%. Past dividends don't guarantee future payments.
What is the ROE of Morepen Laboratories Ltd?
Morepen Laboratories Ltd has ROE of 11.78%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Morepen Laboratories Ltd?
Morepen Laboratories Ltd has debt-to-equity of 0.13.
Is Morepen Laboratories Ltd a good investment?
Bull Run gives Morepen Laboratories Ltd a score of 34.5/100. This is not investment advice — consult a SEBI-registered advisor.